ArticleJournal of cardiology cases2025
Histopathological findings of biodegradable polymer sirolimus eluting stent 7 years after stent implantation.
Article in Journal of cardiology cases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This report analyzes a biodegradable polymer coated drug-eluting stent (DES), Ultimaster (Terumo, Tokyo, Japan), seven years after implantation in a 73-year-old man who died from acute myocardial infarction after discontinuing his medications. Autopsy revealed no in-stent thrombosis or restenosis. Two stents exhibited neoatherosclerosis with calcifying necrotic core and foamy macrophages, indicating a lesser risk of very late stent thrombosis. The findings support the notion that third-generation DES might result in healthier long-term vessel healing and reduced neoatherosclerosis compared to earlier generations, consistent with prior animal studies. This suggests a sustained benefit and safety of the biodegradable polymer coated DES over an extended period. Learning objectives: A 65-year-old male received three 3rd generation biodegradable polymer coated drug-eluting stents (BP-DES), Ultimaster (Terumo, Tokyo, Japan), during percutaneous coronary intervention. Seven years post-implantation, post-mortem histopathological analysis revealed well-healed arterial tissue with near-complete endothelialization and minimal neoatherosclerosis. No significant inflammation or late stent thrombosis was observed, with stent struts embedded in the neointima, indicating favorable long-term vessel healing. This case underscores the long-term biocompatibility of BP-DES, highlighting reduced risks of late stent thrombosis and neointimal hyperplasia over extended follow-up periods.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.